MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Cytek Biosciences Inc

Fechado

SetorSaúde

5.39 -3.92

Visão Geral

Variação de preço das ações

24h

Atual

Mín

5.38

Máximo

5.48

Indicadores-chave

By Trading Economics

Rendimento

105K

-5.5M

Vendas

6.7M

52M

EPS

-0

Margem de lucro

-10.476

Funcionários

692

EBITDA

6.4M

-4.2M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+10.97% upside

Dividendos

By Dow Jones

Próximos Ganhos

26 de fev. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

240M

742M

Abertura anterior

9.31

Fecho anterior

5.39

Sentimento de Notícias

By Acuity

17%

83%

18 / 361 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Cytek Biosciences Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

16 de jan. de 2026, 23:29 UTC

Ações em Alta

Stocks to Watch: Atossa Therapeutics, Union Pacific

16 de jan. de 2026, 22:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 de jan. de 2026, 22:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 de jan. de 2026, 22:22 UTC

Aquisições, Fusões, Aquisições de Empresas

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 de jan. de 2026, 21:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Tech, Media & Telecom Roundup: Market Talk

16 de jan. de 2026, 21:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Auto & Transport Roundup: Market Talk

16 de jan. de 2026, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

16 de jan. de 2026, 21:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

16 de jan. de 2026, 21:48 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 de jan. de 2026, 21:41 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 de jan. de 2026, 21:38 UTC

Aquisições, Fusões, Aquisições de Empresas

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 de jan. de 2026, 21:30 UTC

Aquisições, Fusões, Aquisições de Empresas

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 de jan. de 2026, 21:30 UTC

Aquisições, Fusões, Aquisições de Empresas

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 de jan. de 2026, 21:30 UTC

Aquisições, Fusões, Aquisições de Empresas

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 de jan. de 2026, 21:30 UTC

Aquisições, Fusões, Aquisições de Empresas

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 de jan. de 2026, 21:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 de jan. de 2026, 20:44 UTC

Ganhos

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 de jan. de 2026, 20:42 UTC

Conversa de Mercado

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 de jan. de 2026, 20:28 UTC

Conversa de Mercado

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 de jan. de 2026, 19:12 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 de jan. de 2026, 18:53 UTC

Conversa de Mercado

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 de jan. de 2026, 18:41 UTC

Conversa de Mercado

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 de jan. de 2026, 18:31 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 de jan. de 2026, 17:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

16 de jan. de 2026, 17:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

16 de jan. de 2026, 17:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

16 de jan. de 2026, 17:03 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

16 de jan. de 2026, 17:03 UTC

Conversa de Mercado

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16 de jan. de 2026, 16:32 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16 de jan. de 2026, 16:20 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

Comparação entre Pares

Variação de preço

Cytek Biosciences Inc Previsão

Preço-alvo

By TipRanks

10.97% parte superior

Previsão para 12 meses

Média 6.17 USD  10.97%

Máximo 7.5 USD

Mínimo 5 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Cytek Biosciences Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

3 ratings

2

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

3.7 / 3.8Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

18 / 361 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat